Epidermal reconstructs in vitiligo: An extrinsic factor is needed to trigger the disease

British Journal of Dermatology

Volumn 137, Issue 6, 1997, Pages 890-897

  Bessou, S ^a   Gauthier, Y ^b   Surleve Bazeille J E ^a   Pain, C ^a   Taieb A ^a,b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b HÔPITAL PELLEGRIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; KERATINOCYTE; MELANOCYTE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; VITILIGO;

EID: 0031449728     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.1997.tb01548.x     Document Type: Article

References (43)

1. Nordlund J. The significance of depigmentation. Pigment Cell Res 1992; 2: 237-41.
2. Le Poole IC, Das PK, van den Wijngaard RM et al. Review of the etiopathomechanism of vitiligo: a convergence theory. Exp Dermatol 1993; 2: 145-55.
3. Ortonne JP, Bose SK. Vitiligo: where do we stand? Pigment Cell Res 1993; 6: 61-72.
4. Cui J, Shen LY, Wang GC. Role of hair follicles in the repigmentation of vitiligo. J Invest Dermatol 1991; 97: 410-16.
5. Le Poole IC, van den Wijngaard RM, Westerhof W et al. Presence or absence of melanocytes in vitiligo lesions: an immunohistochemical investigation. J Invest Dermatol 1993; 100: 816-22.
6. Lerner AB, Halaban R, Klaus SN, Moellmann GE. Transplantation of human melanocytes. J Invest Dermatol 1987; 89: 219-27.
7. Brysk MM, Newton RC, Srinivason R et al. Repigmentation of vitiliginous skin by cultured cells. Pigment Cell Res 1989; 2: 202-7.
8. Gauthier Y, Surlève-Bazeille JE. Autologous grafting with non-cultured melanocytes: a simplified method for treatment of depigmented lesions. J Am Acad Dermatol 1992; 26: 191-4.
9. Gauthier Y. Traitements des achromies localisées par greffe mélanocytaire. J Med Esth Chir Derm 1993; 80: 223-6.
10. Medrano EE, Nordlund JJ. Successful culture of adult human melanocytes obtained from normal and vitiligo donors. J Invest Dermatol 1990; 95: 441-5.
11. Jee SH, Kuo YF, Wu YC et al. Growth of human melanocytes from suction blister of localised vitiligo patients and from foreskins of newborns and adults by a modified culture medium. J Formos Med Assoc 1993; 92: 7-14.
12. Im S, Hann SK, Park YK, King H. Culture of melanocytes obtained from normal and vitiligo subjects. Yonsei Med J 1992; 33: 344-50.
13. Purri N, Mojambar M, Ramaiah A. Growth defects of melanocytes in culture from vitiligo subjects are spontaneously corrected in vivo in repigmenting subjects and can be partially corrected by the addition of fibroblast-derived growth factors in vitro. Arch Dermatol Res 1989; 281: 178-84.
14. Boissy RE, Liu Y, Medrano E, Nordlund JJ. Structural aberration of the rough endoplasmic reticulum and melanosome compartmentalization in long-term cultures of melanocytes from vitiligo patients. J Invest Dermatol 1991; 97: 395-404.
15. Im S, Hann SK, Kim HT et al. Biologic characteristics of cultured human vitiligo melanocytes. Int J Dermatol 1994; 33: 556-62.
16. Fitzpatrick TB, Szabò G, Seiji M, Quevedo WC. Biology of the melanin pigmentary system. In: Dermatology in General Medicine (Fitzpatrick TB, Eisen AZ, Wolff K et al., eds), 2nd edn. New York: McGraw-Hill, 1979; 131-63.
17. Bessou S, Surlève-Bazeille JE, Sorbier E, Taïeb A. Ex vivo reconstruction of the epidermis with melanocytes and the influence of UVB. Pigment Cell Res 1995; 8: 241-9.
18. Bessou S, Surlève-Bazeille JE, Pain C et al. Ex-vivo study of skin phototypes. J Invest Dermatol 1996; 107: 684-8.
19. Bessou S, Pain C, Taïeb A. Use of human skin reconstructs in the study of pigment modifiers. Arch Dermatol 1997; 133: 331-6.
20. Fitzpatrick TB. The validity and practicality of sun-reactive skin type I through VI. Arch Dermatol 1988; 124: 869-71.
21. Boisseau AM, Donatien PD, Surlève-Bazeille JE et al. Production of epidermal sheets in a serum free culture system: a further appraisal of the role of extracellular calcium. J Dermatol Sci 1992; 3: 111-20.
22. Donatien PD, Surlève-Bazeille JE, Thody AJ, Taïeb A. Growth and differentiation of normal human melanocytes in a TPA-free, cholera toxin-free, low-serum medium and influence of keratinocytes. Arch Dermatol Res 1993; 285: 385-92.
23. Pruniéras M, Régnier M, Schlotterer M. Nouveau procédé de culture des cellules épidermiques humaines sur derme homologue ou hétérologue: préparation de greffons recombinés. Ann Chir Plast 1979; 24: 357-62.
24. Gabe M. Techniques Histologiques. Paris: Masson, 1968.
25. Staricco RJ, Phikus H. Quantitative and qualitative data on the pigment cells of adult human epidermis. J Invest Dermatol 1957; 28: 33-45.
26. Schallreuter KU, Wood JM, Berger J. Low catalase levels in the epidermis of patients with vitiligo. J Invest Dermatol 1991; 97: 1081-5.
27. Schallreuter KU, Pittelkow MP. Defective calcium uptake in keratinocyte cell cultures from vitiliginous skin. Arch Dermatol Res 1988; 280: 137-9.
28. Schallreuter-Wood KU, Pittelkow RM, Swanson NN. Defective calcium transport in vitiliginous melanocytes. Arch Dermatol Res 1996; 288: 11-13.
29. Schallreuter KU, Pittelkow RM, Wood JM. Free radical reduction by thioredoxin reductase at the surface of normal and vitiliginous human keratinocytes. J Invest Dermatol 1986; 87: 728-32.
30. Schallreuter KU, Wood JM, Ziegler I et al. Defective tetrahydrobiopterin and catecholamine biosynthesis in the depigmentation disorder vitiligo. Biochem Biophys Acta 1994; 1226: 181-92.
31. Schallreuter KU, Wood JM, Pittelkow MR et al. Regulation of melanin biosynthesis in the human epidermis by tetrahydrobiopterin. Science 1994; 263: 1444-6.
32. Schallreuter KU, Wood JM, Pittelkow MR et al. Increased in vitro expression of beta-2 adrenoreceptors in differentiating lesional keratinocytes of vitiligo patients. Arch Dermatol Res 1993; 285: 216-20.
33. Schallreuter KU, Wood JM, Lemke R et al. Production of catecholamines in the human epidermis. Biochem Biophys Res Commun 1992; 189: 72-8.
34. Schallreuter KU, Lemke KR, Pittelkow MR et al. Catecholamines in human keratinocytes differentiation. J Invest Dermatol 1995; 104: 953-7.
35. Schallreuter KU, Wood JM, Pittelkow MR et al. Increased monoaminooxidase activity in the epidermis of patients with vitiligo. Arch Dermatol Res 1996; 288: 11-13.
36. Morrone A, Picardo M, De Luca C et al. Catecholamines and vitiligo. Pigment Cell Res 1992; 5: 65-9.
37. Salzer BA, Schallreuter KU. Investigation of the personality structure in patients with vitiligo and a possible association with impaired catecholamines metabolism. Dermatology 1995; 190: 109-15.
38. Naughton GK, Reggiardo D, Bystryn JC. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol 1986; 15: 978-81.
39. Norris DA, Kissinger PM, Naughton GK, Bystryn JC. Evidence for immunologic mechanism in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. J Invest Dermatol 1988; 90: 781-9.
40. Bystryn JC. Immune mechanisms in vitiligo. Immunology 1989; 57: 448-68.
41. Harning R, Cui J, Bystryn JC. Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol 1991; 97: 1078-80.
42. Yu HS, Kao CH, Yu CL. Coexistence and relationship of antikeratinocyte and antimelanocyte antibodies in patients with non-segmental type vitiligo. J Invest Dermatol 1993; 100: 823-8.
43. Cui J, Arita Y, Bystryn JC. Characterization of vitiligo antigens. Pigment Cell Res 1995; 8: 53-9.